OrthoLogic partnership opportunities
This article was originally published in The Gray Sheet
Executive Summary
Firm's Chrysalis BioTechnology acquisition for $27.5 mil. in cash and stock (plus up to $7 mil. in milestones) stems from an earlier licensing pact for development-phase, Chrysalin synthetic peptide-based therapeutics for orthopedic indications. The purchase provides rights beyond orthopedics: OrthoLogic is considering partnering with a device firm to market a Chrysalin-based cardiovascular drug that could be delivered via catheter for ischemia, CEO Thomas Trotter said April 29. The firm also is pondering partnerships to speed development of five Chrysalin-based products for orthopedic indications (1"The Gray Sheet" Oct. 13, 2003, p. 12)...
You may also be interested in...
OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones
OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.